These participants were split into six groups and each group received a different amount of the medicine: 1
Healthline, updated July 26, 2023
Sources Phase 2 Retatrutide Trial (NEJM) Triple hormone receptor agonist retatrutide for metabolic dysfunctionassociated steatotic liver disease Triple Agonism Review (PMC) Triple Agonism Based Therapies for Obesity Retatrutide Game Changer Review RetatrutideA Game Changer in Obesity Pharmacotherapy The Atlantic GLP3 Underground Market GoodRx Retatrutide Availability & Dosage Retatrutide for Weight Loss: Availability, Dosage, and More Phase 3 Trial Update (Clinical Trials Arena) Lillys triple G agonist boasts 28.7% weight loss in Phase III trial Retatrutide FDA Status 2026 Retatrutide FDA Approval Status 2026: Phase 3 Results Update GLP3 Retatrutide FAQ (Expert) GLP3 Retatrutide Peptide Expert FAQ Dr
Urva, S., Coskun, T., Loh, M
With further research, GLP-1 RAs could expand the therapeutic arsenal for psychiatric care, offering new hope for conditions with limited treatment options
That glucose-dependent mechanism is the key distinction
